Losartan Potassium and Hydrochlorothiazide tablets recalled for AZIDO impurity
Lupin Pharmaceuticals is recalling Losartan Potassium and Hydrochlorothiazide tablets distributed nationwide due to elevated AZIDO impurity levels detected during manufacturing quality control.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The presence of a chemical impurity above acceptable limits in a pharmaceutical product represents a risk-of-harm situation where adverse events have not yet been reported, meeting the rubric criterion for Score 3.
Plain-English summary
Lupin Pharmaceuticals Inc. is recalling multiple lot numbers of Losartan Potassium and Hydrochlorothiazide Tablets USP, 50 mg/12.5 mg, a combination blood pressure medication. The recall affects both 30-count and 90-count bottles that were distributed nationwide. A total of 1,214,016 bottles are involved, with lot numbers dated from 2022 through 2023.
The recall was initiated after current good manufacturing practice (CGMP) deviations revealed elevated levels of AZIDO impurity in affected batches. The impurity levels exceeded acceptable limits. No illnesses or injuries have been reported in connection with these products.
Consumers and healthcare providers who possess this medication should check their lot numbers against the list of recalled batches. If the lot number matches, the medication should be discontinued immediately. Patients should contact their healthcare provider or pharmacist for guidance on obtaining a safe replacement.
The recalled product
- Product
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE)
- Brand
- LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Blood Pressure Medication
- Hazard
- Affected units
- 1,214,016
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
UPCs (2)
- 0368180215066
- 0368180217060
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 6 recalled by Lupin Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 6 products in this recall →Related recalls
Same brand · LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- HighLosartan Potassium and Hydrochlorothiazide Tablets Recalled for Foreign Plastic Contamination
FDA (Drugs) · 2024-05-22
- HighFDA Recalls Losartan-Hydrochlorothiazide Tablets for Manufacturing Quality Deviations
FDA (Drugs) · 2022-07-06
- HighBlood Pressure Medication Losartan-HCTZ Recalled for Impurity Deviation
FDA (Drugs) · 2022-06-08
- HighLosartan Potassium and Hydrochlorothiazide Recall: Impurity Levels Above Acceptable Limits
FDA (Drugs) · 2022-06-01
- HighBlood Pressure Medication Recalled for Manufacturing Impurity
FDA (Drugs) · 2022-06-01
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateGanirelix acetate injection recalled after failing an impurity specification
FDA (Drugs) · 2025-12-17
Same hazard · azido impurity
See all →- HighLosartan Potassium tablets recalled for elevated AZIDO impurity
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for Elevated AZIDO Impurity Levels
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for Manufacturing Impurity Issues
FDA (Drugs) · 2022-07-06
- HighLosartan Potassium Tablets Recalled for CGMP Deviations and Elevated Impurity
FDA (Drugs) · 2022-06-08
- HighLosartan HCTZ tablets recalled for manufacturing impurity levels above acceptable limits
FDA (Drugs) · 2022-06-01